Kyntra Bio Inc

KYNB Healthcare Biotechnology

In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.85 0.51 −9.51%
Market cap
$21.7M
P/E
0.1×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−20.33
Beneish M
−4.57
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
183.45 (47.58) (284.23) (293.65) (290.02) (189.29) (76.97) (86.42) (120.87) (58.07)
Operating Cash Flow
(4.77) (138.00) (315.02) (145.93) (82.23) 81.60 (78.70) (76.14) (66.51) 7.11
Investing cash flow
35.42 125.99 153.66 89.12 (426.97) 452.49 120.02 (522.12) 69.87 6.62
Financing cash flow
(86.03) (0.25) 122.75 46.78 (0.56) 13.34 (4.30) 13.88 496.47 6.74
Ending Cash
47.87 102.18 113.69 155.70 171.22 678.39 126.27 89.26 673.66 173.78
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates